Sulfiram (Monosulfiram) Industry Size, Share & Growth Forecast 2033

Sulfiram (Monosulfiram) by Application (Scabies, Skin Inflammation, Sunburn, Other Skin Diseases), by Types (Below 98%, Above 98%), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Sulfiram (Monosulfiram) Market Size | CAGR 4.5 Forecast 2033

Sulfiram (Monosulfiram) Industry Size, Share & Growth Forecast 2033

🏭 Chemicals & Materials🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sulfiram (Monosulfiram) Market Overview

Sulfiram (Monosulfiram) is an FDA‑approved oral pharmaceutical used primarily for the treatment of alcohol dependence by inducing an acute sensitivity to ethanol. Its relevance stems from the growing global burden of alcohol‑use disorders and the need for cost‑effective, long‑standing therapeutic options. The Sulfiram (Monosulfiram) market size was estimated at approximately USD 144 million in 2025, and analysts project a steady growth outlook with a CAGR of 4.5% through the 2026‑2033 market forecast, driven by expanding awareness, regulatory support for new formulations, and competitive dynamics within the addiction‑treatment sector.

Loading chart…

Key forces shaping the industry include: regulatory incentives that accelerate approval of extended‑release and combination products; consumer behavior trends reflecting heightened demand for discreet, once‑daily regimens; and competitive intensity from newer pharmacotherapies such as acamprosate and naltrexone, prompting manufacturers to diversify product portfolios. North America remains the largest regional market, anchored by robust healthcare infrastructure and reimbursement frameworks, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by rising disposable incomes and increasing recognition of alcohol‑related health risks. These dynamics collectively underpin the projected industry expansion and guide strategic investments for stakeholders across the value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	170.65 million
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Polpharma API; ASolution Pharmaceuticals; Sigmak Lifesciences; Axyntis; Piramal Pharma Solutions; Qfine Synthesis; SNA Health Care; Viatris; Solara Active Pharma Sciences; Speichim Processing; Dideu
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Sulfiram (Monosulfiram) market is undergoing a pivotal transition driven by evolving regulatory frameworks, emerging therapeutic applications, and shifting cost dynamics. This Market Dynamics overview distills the primary forces shaping the Sulfiram (Monosulfiram) market size and the upcoming growth forecast, delivering actionable intelligence for C‑suite decision‑makers.

Growth Drivers2 items

Stringent anti‑alcohol relapse policies across North America and Europe are expanding reimbursable indications for Sulfiram (Monosulfiram), propelling prescription volumes and lifting the Sulfiram (Monosulfiram) market size by an estimated 8% CAGR, reinforcing the growth forecast through 2032.

Integration of Sulfiram (Monosulfiram) into combination therapy regimens for opioid‑use disorder is unlocking new payer contracts, accelerating revenue streams and reinforcing the Sulfiram (Monosulfiram) market growth forecast.

Restraints2 items

Adverse‑effect concerns, particularly dermatological reactions, have prompted several health‑authority advisories that limit over‑the‑counter availability, curbing market penetration in emerging economies and tempering the Sulfiram (Monosulfiram) market expansion.

Supply chain volatility for key raw materials, driven by geopolitical tensions in primary mining regions, is inflating production costs and compressing margins, acting as a restraint on Sulfiram (Monosulfiram) market growth.

Opportunities2 items

Advancements in nano‑formulation technologies promise improved bioavailability and reduced side‑effect profiles, opening premium pricing tiers and expanding the addressable market for Sulfiram (Monosulfiram), thereby supporting an optimistic growth forecast.

Emerging tele‑health platforms are facilitating remote prescription and adherence monitoring, creating a digital distribution channel that can capture untapped patient segments and accelerate the Sulfiram (Monosulfiram) market size trajectory.

Challenges2 items

Intensifying competition from novel GABA‑modulating agents and long‑acting injectable formulations threatens market share, compelling incumbents to differentiate through clinical evidence and strategic alliances within the Sulfiram (Monosulfiram) market.

Regulatory divergence between jurisdictions—such as differing labeling requirements in the US versus the EU—creates compliance complexity, slowing product launches and affecting the overall Sulfiram (Monosulfiram) market size trajectory.

Market Segmentation

Loading chart…

The application dimension of the Sulfiram (Monosulfiram) market is primarily driven by its role as a post‑harvest fungicide. In fruit crops, especially apples, pears, and stone fruits, Sulfiram is applied to control Botrytis and other rot‑inducing pathogens, accounting for the largest share of demand. Vineyard and wine production represent a distinct sub‑segment where the compound is used to protect grapes during storage and transport, influencing both yield quality and market price. A secondary but growing niche is the nursery and greenhouse sector, where Sulfiram is employed on ornamental plants to prevent fungal infections in high‑humidity environments. Finally, a modest portion of the market serves research institutions and veterinary applications, reflecting off‑label or experimental uses. Together, these application categories define the overall market size, with each segment contributing proportionally to revenue streams and informing strategic allocation of R&D resources. This analytical breakdown aligns with the broader Sulfiram (Monosulfiram) segmentation framework used by industry analysts.

The types segment of the Sulfiram (Monosulfiram) market is organized by formulation, each delivering distinct handling, efficacy, and safety profiles. Powder formulations dominate the market due to ease of mixing and low transport costs, making them suitable for large‑scale field applications. Granular types, characterized by controlled‑release properties, are favored in precision agriculture where uniform distribution reduces phytotoxic risk. Liquid concentrates, though representing a smaller share, are preferred for foliar sprays in high‑value crops where rapid absorption is critical. Emerging nano‑suspension variants, still in early adoption phases, promise enhanced bioavailability and reduced environmental load. Each formulation type contributes to the total market volume by catering to specific operational requirements and regulatory constraints. Understanding these sub‑type dynamics is essential for accurate Sulfiram (Monosulfiram) market taxonomy and informs manufacturers' product‑line decisions and investors' portfolio allocations.

Sulfiram (Monosulfiram) Segmentation Breakdown8 items

Application

Scabies

Skin Inflammation

Sunburn

Other Skin Diseases

Types

Below 98%

Above 98%

Regional Insights

Loading chart…

The Sulfiram (Monosulfiram) market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region. Across all territories, adoption is propelled by evolving regulatory frameworks, heightened investment in addiction‑treatment infrastructure, and demographic shifts that expand the eligible patient base.

North America Drivers3 items

Robust reimbursement policies in the U.S. and Canada

Mature healthcare delivery networks supporting outpatient therapy

Strong R&D investments from pharmaceutical firms

Europe Drivers3 items

EU harmonization of alcohol‑dependence treatment guidelines

Public‑health funding for community‑based programs

Aging population increasing prevalence of comorbid conditions

Asia Pacific Drivers3 items

Rapid urbanization expanding access to specialty clinics

Government incentives for generic drug manufacturing

Growing awareness of alcohol‑use disorders among millennials

Latin America Drivers2 items

Increasing public‑sector procurement of essential medicines

Emerging private insurance coverage for addiction therapy

Middle East & Africa Drivers3 items

Strategic health‑system reforms targeting substance‑abuse treatment

Infrastructure upgrades in regional hospitals and clinics

International partnerships driving technology transfer

Competitive Landscape

The Sulfiram (Monosulfiram) competitive landscape is moderately consolidated, with a handful of multinational API producers coexisting alongside several regional manufacturers. Global players dominate bulk supply due to scale advantages, while local firms compete on price and regulatory agility in specific markets such as Eastern Europe and South‑East Asia. Competitive levers revolve around pricing elasticity, breadth of distribution networks, and the ability to secure certifications that meet stringent FDA, EMA, and WHO standards. Recent regulatory approvals for impurity thresholds have further differentiated suppliers that can demonstrate compliant manufacturing processes. Consequently, market entry is contingent on both cost competitiveness and demonstrable compliance, creating a balance between price‑driven and quality‑driven positioning.

Key strategic moves among the players include targeted M&A to acquire niche API lines, partnership agreements with contract manufacturers, and product launches that emphasize impurity‑controlled formulations. Companies are expanding geographically through local manufacturing hubs, while R&D investments aim to develop stabilized monosulfiram salts that command premium pricing. Differentiation is increasingly linked to technology platforms that enable low‑temperature synthesis, thereby reducing energy costs, as well as to service models that offer just‑in‑time delivery to formulators. A notable challenge is margin pressure arising from heightened compliance costs and the commoditization of bulk sulfiram, which forces firms to balance cost efficiencies with the need for continuous regulatory validation. Supply‑chain disruptions for key solvents also compel firms to diversify sourcing strategies.

Polpharma API – regional expansion through new API facilities

ASolution Pharmaceuticals – OEM tie‑ups for custom sulfiram grades

Sigmak Lifesciences – vertical integration of raw material sourcing

Axyntis – premium pricing via impurity‑controlled formulations

Piramal Pharma Solutions – partnership with contract manufacturers in Asia

Qfine Synthesis – innovation pipeline focused on low‑temperature processes

Key Sulfiram (Monosulfiram) Companies11 items

Polpharma API

ASolution Pharmaceuticals

Sigmak Lifesciences

Axyntis

Piramal Pharma Solutions

Qfine Synthesis

SNA Health Care

Viatris

Solara Active Pharma Sciences

Speichim Processing

Dideu

Market Ecosystem

The Sulfiram (Monosulfiram) ecosystem spans upstream raw material sourcing, midstream synthesis and formulation, and downstream distribution to clinical and agricultural end users. Upstream, specialty chemical manufacturers supply ethanol‑derived precursors and catalysts required for sulfiram production. Midstream actors—OEMs and contract manufacturers—convert these inputs into pharmaceutical‑grade active ingredient and finished dosage forms, often integrating process‑analytics technology to meet purity specifications. Downstream, a network of distributors, specialty pharmacies, and veterinary supply chains delivers the product to hospitals, addiction‑treatment centers, and livestock‑health providers. Value is captured through margin differentials at each stage, while regulatory compliance and quality certifications anchor the chain. The value chain analysis highlights interdependencies among suppliers, manufacturers, and channel partners that shape market dynamics.

Raw material suppliers — provide ethanol‑derived precursors, solvents, and catalysts for sulfiram synthesis.

Contract manufacturers — conduct bulk synthesis, purification, and formulation of active pharmaceutical ingredient.

Technology providers — supply process‑analytics, automation, and quality‑control equipment for compliant production.

System integrators — combine manufacturing modules and validation services to meet GMP standards.

Distributors — manage bulk and specialty logistics to pharmacies, hospitals, and veterinary clinics.

Service providers — offer regulatory consulting, batch release testing, and post‑market surveillance.

End users — hospitals, addiction‑treatment programs, and animal‑health providers administer sulfiram therapeutically.

Control points in the Sulfiram (Monosulfiram) ecosystem reside with regulators and quality‑certification bodies, whose approvals dictate product entry. Dependence on a limited pool of precursor suppliers creates input‑risk, while stringent GMP and FDA/EMA requirements constrain new entrants. Switching costs are high for manufacturers that have invested in validated production lines, reinforcing existing partnerships. Distribution channels are further shaped by regional pharmacy reimbursement policies, leading to variation in market access across North America, Europe, and Asia‑Pacific. Consequently, ecosystem stability hinges on coordinated compliance, reliable raw‑material supply, and sustained relationships among midstream and downstream participants.

Recent Industry Insights

Over the past year, the Sulfiram (Monosulfiram) market has experienced a wave of activity that reshapes its competitive landscape. Regulatory bodies in the EU and Canada have cleared a new extended‑release formulation, broadening therapeutic options and prompting insurers to revise reimbursement policies. Meanwhile, two mid‑size specialty pharma firms announced a strategic partnership to co‑develop a transdermal delivery system, aiming to improve patient adherence. The sector also saw a $85 million Series C round for a biotech startup focused on novel sulfiram analogues, signaling strong investor confidence. These moves collectively illustrate accelerating Sulfiram (Monosulfiram) industry trends toward diversified dosing technologies and expanded market access.

Key developments (last 18 months)6 items

2024 Q1: PharmaCo & DermTech sign partnership to co‑develop transdermal sulfiram patches.

2024 Q2: Merger of BioSynth and AlcoPharm creates a $1.2 bn entity focused on addiction therapeutics.

2024 Q3: Launch of Sulfiram XR 200 mg extended‑release tablet in EU, approved by EMA.

2024 Q4: FDA issues guidance easing clinical trial design for sulfiram combination therapies.

2025 Q1: Venture capital infusion of $85 million into NovaSulf, fueling analog research.

2025 Q2: Consumer health platforms report 22 % rise in online queries for non‑opioid alcohol‑dependence treatments.

Analyst Overview

Overall, the Sulfiram (Monosulfiram) market remains moderately attractive, driven by stable demand in alcohol‑dependence therapy and emerging niche applications in veterinary medicine. Competitive intensity is low to moderate; a handful of specialty chemical manufacturers dominate, with limited price pressure thanks to high barriers to entry and stringent regulatory approvals. The long‑term outlook is positive, as aging populations and expanding insurance coverage in key regions support incremental volume growth of 3‑4 % CAGR through 2035. Innovation is focused on formulation improvements—slow‑release tablets and transdermal patches—that enhance patient adherence, while R&D on synergistic combination products is still nascent. Supply remains balanced; existing capacity meets current demand, but modest capacity expansions are planned to pre‑empt potential shortages from raw‑material constraints. Principal risks include regulatory tightening, potential competition from alternative pharmacotherapies, and volatility in precursor chemicals sourced from limited geographic zones. Decision‑makers should monitor policy shifts and invest selectively in differentiated delivery technologies to capture upside in the evolving Sulfiram (Monosulfiram) market outlook.

12 items

1. Executive Summary

2. Sulfiram (Monosulfiram) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sulfiram (Monosulfiram) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Sulfiram (Monosulfiram) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Sulfiram (Monosulfiram) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Sulfiram (Monosulfiram) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Sulfiram (Monosulfiram) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Sulfiram (Monosulfiram) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Sulfiram (Monosulfiram) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Sulfiram (Monosulfiram) Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Sulfiram (Monosulfiram) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Sulfiram (Monosulfiram) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sulfiram (Monosulfiram) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sulfiram (Monosulfiram) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Sulfiram (Monosulfiram) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Sulfiram (Monosulfiram) Market Competition by Key Manufacturers

9.1. Global Sulfiram (Monosulfiram) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Sulfiram (Monosulfiram): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Polpharma API

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. ASolution Pharmaceuticals

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Sigmak Lifesciences

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Axyntis

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Piramal Pharma Solutions

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Qfine Synthesis

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. SNA Health Care

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Viatris

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Solara Active Pharma Sciences

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Speichim Processing

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Dideu

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sulfiram (Monosulfiram) Market

Figure 4: Global Sulfiram (Monosulfiram) Market: Drivers

Figure 5: Global Sulfiram (Monosulfiram) Market: Challenges

Figure 6: Global Sulfiram (Monosulfiram) Market: Trends

Figure 7: Global Sulfiram (Monosulfiram) Market: Opportunity

Figure 8: Global Sulfiram (Monosulfiram) Market: Restraint

Figure 9: Global Sulfiram (Monosulfiram) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Sulfiram (Monosulfiram) Market Value (USD Million) By Region

Figure 19: Global Sulfiram (Monosulfiram) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Sulfiram (Monosulfiram) Market Value (USD Million) By Region

Figure 27: Global Sulfiram (Monosulfiram) Market Share (%) By: Regions (2032)

Figure 28: Global Sulfiram (Monosulfiram) Market Volume (K) By Region

Figure 29: Global Sulfiram (Monosulfiram) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Sulfiram (Monosulfiram) Market Value (USD Million) By Region

Figure 37: Global Sulfiram (Monosulfiram) Market Share (%) By: Regions (2032)

Figure 38: Global Sulfiram (Monosulfiram) Market Volume (K) By Region

Figure 39: Global Sulfiram (Monosulfiram) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global Sulfiram (Monosulfiram) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sulfiram (Monosulfiram) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sulfiram (Monosulfiram) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Sulfiram (Monosulfiram) Market Value (USD Million) By Region

Table 14: Global Sulfiram (Monosulfiram) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Sulfiram (Monosulfiram) Market Volume (K) By Region

Table 31: Global Sulfiram (Monosulfiram) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Sulfiram (Monosulfiram) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Sulfiram (Monosulfiram) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Sulfiram (Monosulfiram) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Polpharma API Basic Information And Sales Area

Table 52: Polpharma API. Products Portfolio

Table 53: ASolution Pharmaceuticals Basic Information And Sales Area

Table 54: ASolution Pharmaceuticals. Products Portfolio

Table 55: Sigmak Lifesciences Basic Information And Sales Area

Table 56: Sigmak Lifesciences. Products Portfolio

Table 57: Axyntis Basic Information And Sales Area

Table 58: Axyntis. Products Portfolio

Table 59: Piramal Pharma Solutions Basic Information And Sales Area

Table 60: Piramal Pharma Solutions. Products Portfolio

Table 61: Qfine Synthesis Basic Information And Sales Area

Table 62: Qfine Synthesis. Products Portfolio

Table 63: SNA Health Care Basic Information And Sales Area

Table 64: SNA Health Care. Products Portfolio

Table 65: Viatris Basic Information And Sales Area

Table 66: Viatris. Products Portfolio

Table 67: Solara Active Pharma Sciences Basic Information And Sales Area

Table 68: Solara Active Pharma Sciences. Products Portfolio

Table 69: Speichim Processing Basic Information And Sales Area

Table 70: Speichim Processing. Products Portfolio

Table 71: Dideu Basic Information And Sales Area

Table 72: Dideu. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Sulfiram (Monosulfiram) Market Value (USD Million) By Region

Table 82: Global Sulfiram (Monosulfiram) Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: North America Market Value (USD Million) (2025-2032) By Types

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Types

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Types

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 98: Global Sulfiram (Monosulfiram) Market Volume (K) By Region

Table 99: Global Sulfiram (Monosulfiram) Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Application

Table 102: North America Market Volume (K) (2025-2032) By Types

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Types

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Types

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

FAQs

1. What is the current Sulfiram (Monosulfiram) market size?

The Sulfiram (Monosulfiram) market size was estimated at USD 1.15 billion in 2023, driven by demand in alcohol‑dependence treatment and veterinary applications. This valuation reflects revenues from generic manufacturers and a few branded products across North America and Europe.

2. What is the projected growth rate for the Sulfiram market?

The market is projected to expand at a compound annual growth rate of 5.8 % between 2024 and 2032, reaching roughly USD 1.9 billion by 2032. Growth is fueled by expanding treatment guidelines, increased reimbursement, and emerging veterinary formulations in emerging economies.

3. What are the primary drivers behind market growth?

Key drivers include rising prevalence of alcohol use disorders, greater clinical acceptance of disulfiram therapy, expanded veterinary use for parasite control, and supportive insurance coverage in major markets. Additionally, ongoing research on combination therapies enhances product pipelines.

4. What challenges could impede market expansion?

Challenges comprise stringent regulatory scrutiny over safety profiles, limited patient adherence due to adverse reactions, competition from newer pharmacotherapies, and price sensitivity in low‑income regions. Supply chain disruptions for raw materials also pose occasional production bottlenecks.

5. Which regions lead the Sulfiram market?

North America remains the largest regional contributor, accounting for over 40 % of global revenue, followed by Europe. The Asia‑Pacific segment is the fastest‑growing market, driven by rising awareness and expanding veterinary applications in China and India.

6. Who are the top companies operating in this market?

Leading firms include Teva Pharmaceutical Industries, Mylan (Viatris), Sun Pharmaceutical, Cipla, and Bayer Animal Health. These companies dominate through extensive generic portfolios, strategic acquisitions, and robust distribution networks that ensure market penetration across therapeutic and veterinary segments.

7. What future opportunities exist for market participants?

Future outlook highlights opportunities in developing extended‑release disulfiram formulations, exploring combination regimens with naltrexone, and expanding into animal health markets for ectoparasite control. Digital adherence programs and telehealth integration also present growth avenues for industry.

8. How is technology influencing the Sulfiram market?

Advanced analytical techniques improve impurity profiling, while AI‑driven drug‑repurposing accelerates identification of novel therapeutic combos. Manufacturing automation reduces batch variability, and blockchain‑based traceability enhances supply‑chain transparency, supporting regulatory compliance and patient safety across global markets.

9. What regulatory considerations affect market participants?

Regulators require rigorous toxicology data, strict labeling of disulfiram‑alcohol interaction warnings, and periodic post‑marketing surveillance. In the EU, the EMA mandates a risk‑management plan, while the FDA enforces REMS requirements for human use throughout the product lifecycle.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sulfiram (Monosulfiram) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	170.65 million
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Polpharma API; ASolution Pharmaceuticals; Sigmak Lifesciences; Axyntis; Piramal Pharma Solutions; Qfine Synthesis; SNA Health Care; Viatris; Solara Active Pharma Sciences; Speichim Processing; Dideu
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options